T. Rowe Price Investment Management, Inc. Immunovant, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $158 Billion
- Q2 2025
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Immunovant, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 6,878,956 shares of IMVT stock, worth $189 Million. This represents 0.07% of its overall portfolio holdings.
Number of Shares
6,878,956
Previous 5,894,824
16.69%
Holding current value
$189 Million
Previous $101 Million
9.25%
% of portfolio
0.07%
Previous 0.07%
Shares
5 transactions
Others Institutions Holding IMVT
# of Institutions
191Shares Held
78.7MCall Options Held
401KPut Options Held
354K-
Deep Track Capital, LP Greenwich, CT9.5MShares$261 Million9.27% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.03MShares$193 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY5.46MShares$150 Million1.52% of portfolio
-
Armistice Capital, LLC New York, NY5.2MShares$143 Million2.5% of portfolio
-
Black Rock Inc. New York, NY4.92MShares$135 Million0.0% of portfolio
About Immunovant, Inc.
- Ticker IMVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 129,077,000
- Market Cap $3.55B
- Description
- Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...